Answers are grounded in this paper and cite their sources.
Systemic application aims to deliver oncolytic viruses to tumors as well as to metastatic lesions. However, we found that xenoantigens incorporated onto the viral surface from nonhuman production cell lines are recognized by natural antibodies in human serum and that the virus is thereby inactivated by complement lysis. Hence, to maximize the effective dose, careful selection of cell lines for virus production is crucial.
No takes yet. Share an insight, caveat, or question.
Pipperger et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: